Back to Search
Start Over
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure
- Source :
- JACC: Heart Failure; July 2022, Vol. 10 Issue: 7 p498-507, 10p
- Publication Year :
- 2022
-
Abstract
- The endothelin receptor antagonist atrasentan reduced the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease (CKD) in the SONAR (Study of Diabetic Nephropathy with Atrasentan) trial, although with a numerically higher incidence of heart failure (HF) hospitalization.
Details
- Language :
- English
- ISSN :
- 22131779
- Volume :
- 10
- Issue :
- 7
- Database :
- Supplemental Index
- Journal :
- JACC: Heart Failure
- Publication Type :
- Periodical
- Accession number :
- ejs60234292
- Full Text :
- https://doi.org/10.1016/j.jchf.2022.03.004